Crizotinib, a first generation tyrosine kinase inhibitor acts on ROS-1, MET and ALK, promoting longer progression free survival in NSCLC when compared to traditional chemotherapy [29]. This evidence concerns the gene ALK and non-small cell lung carcinoma.